Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 293.6Cr 335.51Cr 269.76Cr 251.45Cr 475.92Cr 32TCr 484.89Cr 3.25TCr 1.26TCr 16TCr 1.26TCr 1.23TCr 54TCr P/E 2026 *
21.9x
P/E 2027 * 16.5x
Enterprise Value 290.81Cr 332.32Cr 267.19Cr 249.06Cr 471.4Cr 32TCr 480.28Cr 3.22TCr 1.25TCr 16TCr 1.25TCr 1.22TCr 54TCr EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.17x
Free-Float
31.63%
Yield 2026 *
1.7%
Yield 2027 * 1.95%
3 years 50.88
Extreme 50.88
90.61
5 years 0.03
Extreme 0.03
90.61
10 years 0.03
Extreme 0.03
90.61
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
-27.31%-.--% - - 334.98Cr
+1.86%+8.65%+56.45%+158.84% 1,06300Cr
+3.57%+9.15%+68.70%+58.92% 61TCr
+3.99%+11.15%+37.41%+93.77% 44TCr
-1.20%-0.96%+26.12%+20.22% 32TCr
+4.94%+4.51%+39.76%+28.93% 29TCr
+2.42%+2.96%+30.77%+42.24% 28TCr
+2.47%+6.56%-24.26%-39.60% 22TCr
+3.55%+6.47%+28.79%+68.52% 20TCr
+4.21%+4.88%+17.49%+70.33% 16TCr
Average -1.40%+2.83%+31.25%+55.80% 39.79TCr
Weighted average by Cap. +0.23%+4.16%+41.94%+80.68%

Financials

2026 *2027 *
Net sales 77Cr 88Cr 71Cr 66Cr 125.47Cr 8.44TCr 127.83Cr 855.92Cr 331.94Cr 4.14TCr 332.29Cr 324.99Cr 14TCr 90Cr 102.64Cr 83Cr 77Cr 145.6Cr 9.8TCr 148.34Cr 993.23Cr 385.19Cr 4.8TCr 385.6Cr 377.13Cr 17TCr
Net income 13Cr 15Cr 12Cr 11Cr 22Cr 1.45TCr 22Cr 147.05Cr 57Cr 711.02Cr 57Cr 56Cr 2.45TCr 18Cr 20Cr 16Cr 15Cr 29Cr 1.94TCr 29Cr 196.39Cr 76Cr 949.59Cr 76Cr 75Cr 3.27TCr
Net Debt -2.79Cr -3.19Cr -2.56Cr -2.39Cr -4.52Cr -303.99Cr -4.6Cr -31Cr -12Cr -149.02Cr -12Cr -12Cr -513.71Cr -8.59Cr -9.82Cr -7.89Cr -7.36Cr -14Cr -936.87Cr -14Cr -95Cr -37Cr -459.27Cr -37Cr -36Cr -1.58TCr
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
1,998
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
57.40EUR
Average target price
75.38EUR
Spread / Average Target
+31.32%

Quarterly revenue - Rate of surprise